Groundbreaking Gene Therapy Offers Hope for Hunter Syndrome Patient

Introducing Oliver Chu

A remarkable story is unfolding in the realm of medical science, centered around Oliver Chu, a three-year-old boy who has become the first ever recipient of a pioneering gene therapy for Hunter syndrome, a rare and debilitating genetic condition. The disease, also known as MPS II, results in severe progressive damage to the body and brain, and in its most severe form, can lead to death before the age of 20. Before receiving this innovative treatment, Oliver suffered from a deficiency of the enzyme iduronate-2-sulfatase (IDS), essential for maintaining the health of his cells.

A Novel Approach to Treatment

The breakthrough treatment took place at the Royal Manchester Children’s Hospital, where a team of medical professionals, led by Professor Simon Jones, undertook an unprecedented step: they modified Oliver’s own cells using gene therapy to halt the progression of his condition. “I’ve waited 20 years to see a boy like Ollie doing as well as he is, and it’s just so exciting,” remarked Prof. Jones, reflecting on the significance of this trial.

The Chu family, hailing from California, entrusted this uncharted journey to the medical team, making Oliver the first of five boys globally to take part in this trial. Remarkably, within a year of starting the treatment, Oliver showed signs of normal development, raising hopes among his family. “Every time we talk about it, I want to cry because it’s just so amazing,” said his mother, Jingru.

The Initial Steps: Stem Cell Collection

Oliver’s journey began with a crucial procedure in December 2024, where he underwent the first step of treatment: the collection of stem cells from his blood. This step is vital for the subsequent gene modification process. Dr. Claire Horgan, a consultant pediatric haematologist, explained that specific stem cells were harvested to be sent to a lab where they would undergo a genetic alteration aimed at restoring the missing enzyme function.

Patients with Hunter syndrome, while born seemingly healthy, start to manifest symptoms around the age of two. These symptoms can include a range of physical changes and, eventually, severe cognitive decline, making early intervention critical.

The Science Behind the Therapy

At Great Ormond Street Hospital in London, the collected stem cells would be modified with a working copy of the faulty gene. A specially engineered virus serves as a delivery vehicle, allowing the healthy IDS gene to enter the stem cells. Once reintroduced to Oliver, these altered cells are expected to produce normal levels of the missing enzyme, which is critical for breaking down sugar molecules that accumulate due to the genetic defect.

There remains concern about ensuring that sufficient levels of the enzyme reach the brain, prompting modifications to the gene to enhance its ability to cross the blood-brain barrier effectively.

Infusion Day: A Moment of Anticipation

The infusion of the gene-edited stem cells took place in February 2025, marking a significant milestone in Oliver’s treatment journey. While Jingru remained by his side, Ricky stayed in California with Oliver’s older brother, Skyler, also diagnosed with Hunter syndrome. As Oliver lay in a hospital bed, the medical team carefully prepared for the infusion. Moments later, the modified stem cells were introduced into his system through a catheter.

Despite the seriousness of the event, Oliver’s attention remained focused on cartoons, perhaps oblivious to the potential life-altering outcomes of the therapy.

Early Signs of Progress

In May 2025, the family returned to Manchester for crucial follow-up tests. The results painted a positive picture; Oliver appeared more active and engaged, demonstrating significant improvements in his mobility and speech. “He’s doing really well,” Ricky expressed, noting that Oliver had now stopped needing the weekly enzyme infusions that had previously been a part of his life.

Jingru reflected, “Every time we talk about it, I want to cry because it’s simply amazing,” capturing the family’s overwhelming relief and joy.

Long-Term Outlook and Continued Monitoring

The family continues to visit Manchester every three months for ongoing evaluation of Oliver’s condition. Nine months post-therapy, updates confirmed that he was thriving and producing a functional enzyme. Prof. Jones, noting the tremendous advantage of Oliver’s success, stated, “Before the treatment, Ollie didn’t make any enzyme; now he’s making hundreds of times the normal amount.”

This innovative approach may also pave the way for future treatments not just for Hunter syndrome but for other genetic conditions as well.

The Chu family remains optimistic, expressing gratitude for the groundbreaking work being done at the Manchester hospital. Their journey has highlighted the profound impact of gene therapy in treating rare genetic disorders and offers hope not only for Oliver but thousands of others as well.